Press release from Companies
Published: 2014-04-10 14:55:55
WntResearch AB today announces that it has received a Notice of Allowance from the Canadian patent office for its Foxy-5 patent application. The claims of the allowed patent application cover the company’s lead compound Foxy-5 and other related peptides, the use of such peptides as well as pharmaceutical compositions comprising such peptides. WntResearch has already been granted patents covering Foxy-5 in Australia, China, Japan and the United States. Foxy-5 is currently in a phase 1 dose escalating study in patients with solid breast, colorectal or prostate tumours.
CEO Nils Brünner comments: “I’m very pleased to announce that our patent strategy for WntResearch’s lead compound Foxy-5 has been successfully carried through this time in Canada. Patents for Foxy-5 have already been granted in Australia, China, Japan and the United States.” For further information please contact: Nils Brünner, CEO E-mail: nbr@wntresearch.com Telephone: +45 2614 4708 About Foxy-5 Foxy-5 has a significant market potential within oncology. Foxy-5 represents a first-in-class concept for the treatment of cancer. The study drug targets the metastatic process that is the primary reason for cancer deaths. Foxy-5 is one of the first anti-metastatic products ever to enter clinical trials. Foxy-5 offers a potential paradigm shift to influence the treatment of many large cancer indications including breast-, colon and prostate cancer. About WntResearch AB WntResearch (WNT.ST) is a public company listed at AktieTorget. WntResearch is developing novel anti-metastatic therapies for the treatment of cancer patients. The company’s lead product Foxy-5 is in phase 1.
